{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T07:30:02Z","timestamp":1779003002178,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Zinc deficiency is common in chronic liver disease and is closely associated with the progression of hepatic fibrosis and metabolic dysfunction. Although pemafibrate, a selective peroxisome proliferator-activated receptor alpha modulator, has had beneficial effects on lipid metabolism, inflammation, and oxidative stress, its impact on zinc metabolism in patients with metabolic dysfunction-associated steatohepatitis (MASH) remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective study involved patients with biopsy-confirmed MASH complicated by hypertriglyceridemia (fasting triglycerides\u2009\u2265\u2009150\u00a0mg\/dL) who were treated with pemafibrate (0.2\u00a0mg twice daily). Serum zinc levels were evaluated at baseline and at 6, 12, 24, and 36 months after initiation of treatment. Subgroup analyses were performed according to cirrhosis status and baseline serum zinc level (&lt;\u200980\u00a0\u00b5g\/dL vs. \u226580\u00a0\u00b5g\/dL). Changes in liver-related biochemical parameters and albumin levels were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-six patients (mean age 56.3\u2009\u00b1\u200912.6 years; 17 men) were followed for 36 months. Serum zinc levels had increased significantly at 6 months after initiation of pemafibrate and remained significantly elevated through to 36 months. Patients without cirrhosis showed a sustained increase in serum zinc levels throughout the observation period, whereas those with cirrhosis had a delayed and transient response. The serum zinc level increased earlier in patients with zinc deficiency at baseline than in those with a preserved level at baseline. Serum albumin levels increased significantly up to 24 months but not up to 36 months, whereas serum zinc levels remained elevated, suggesting the involvement of albumin-independent mechanisms. Pemafibrate therapy was also associated with significant improvements in triglycerides, liver enzymes, and fibrosis-related markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pemafibrate therapy was associated with a significant and sustained increase in the serum zinc level in patients with hypertriglyceridemia-related MASH, even in the absence of zinc supplementation. However, given the small sample size, the absence of a control group, and the single-arm study design, future large-scale multicenter studies that include a greater number of patients are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-026-04806-5","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T11:17:12Z","timestamp":1775733432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pemafibrate therapy increases serum zinc levels in patients with metabolic dysfunction\u2013associated steatohepatitis: a prospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Noritaka","family":"Wakui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Nagumo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naho","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihide","family":"Mouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Yoshimine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Mukozu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"4806_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nutres.2019.11.009","volume":"74","author":"K Katayama","year":"2020","unstructured":"Katayama K. Zinc and protein metabolism in chronic liver diseases. Nutr Res. 2020;74:1\u20139.","journal-title":"Nutr Res"},{"key":"4806_CR2","first-page":"93","volume":"11","author":"AS Prasad","year":"1995","unstructured":"Prasad AS. Zinc: an overview. Nutrition. 1995;11:93\u20139.","journal-title":"Nutrition"},{"key":"4806_CR3","first-page":"359","volume":"47","author":"H Yanagisawa","year":"2004","unstructured":"Yanagisawa H. Zinc deficiency and clinical practice. Jpn Med Assoc J. 2004;47:359\u201364.","journal-title":"Jpn Med Assoc J"},{"key":"4806_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3164\/jcbn.14-33","volume":"55","author":"K Iwata","year":"2014","unstructured":"Iwata K, Enomoto H, Nishiguchi S, Aizawa N, Sakai Y, Iwata Y, et al. Serum zinc value in patients with hepatitis virus-related chronic liver disease: association with the histological degree of liver fibrosis and with the severity of varices in compensated cirrhosis. J Clin Biochem Nutr. 2014;55:147\u201352.","journal-title":"J Clin Biochem Nutr"},{"key":"4806_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1248\/bpb.25.426","volume":"25","author":"A Nakayama","year":"2002","unstructured":"Nakayama A, Fukuda H, Ebara M, Hamasaki H, Nakajima K, Sakurai H. A new diagnostic method for chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma based on serum metallothionein, copper, and zinc levels. Biol Pharm Bull. 2002;25:426\u201331.","journal-title":"Biol Pharm Bull"},{"key":"4806_CR6","first-page":"4667","volume":"18","author":"L Cai","year":"1998","unstructured":"Cai L, Wang GJ, Xu ZL, Deng DX, Chakrabarti S, Cherian MG. Metallothionein and apoptosis in primary human hepatocellular carcinoma (HCC) from northern China. Anticancer Res. 1998;18:4667\u201372.","journal-title":"Anticancer Res"},{"key":"4806_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"4806_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389\u201398.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4806_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4103\/2008-7802.188083","volume":"7","author":"H Zolfaghari","year":"2016","unstructured":"Zolfaghari H, Askari G, Siassi F, Feizi A, Sotoudeh G. Intake of nutrients, fiber, and sugar in patients with nonalcoholic fatty liver disease in comparison to healthy individuals. Int J Prev Med. 2016;7:98.","journal-title":"Int J Prev Med"},{"key":"4806_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.nut.2006.09.004","volume":"23","author":"K Toshimitsu","year":"2007","unstructured":"Toshimitsu K, Matsuura B, Ohkubo I, Niiya T, Furukawa S, Hiasa Y, et al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition. 2007;23:46\u201352.","journal-title":"Nutrition"},{"key":"4806_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/nu10010088","volume":"10","author":"T Himoto","year":"2018","unstructured":"Himoto T, Masaki T. Associations between zinc deficiency and metabolic abnormalities in patients with chronic liver disease. Nutrients. 2018;10:88.","journal-title":"Nutrients"},{"key":"4806_CR12","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356.","journal-title":"J Hepatol"},{"key":"4806_CR13","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","volume":"80","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Paik JM, Stepanova M, Ong J, Alqahtani S, Henry L. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 2024;80:694\u2013701.","journal-title":"J Hepatol"},{"key":"4806_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3350\/cmh.2023.0515","volume":"30","author":"M Iwaki","year":"2024","unstructured":"Iwaki M, Fujii H, Hayashi H, Toyoda H, Oeda S, Hyogo H, et al. Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: a sub-analysis of the CLIONE study. Clin Mol Hepatol. 2024;30:225\u201334.","journal-title":"Clin Mol Hepatol"},{"key":"4806_CR15","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1016\/j.jhep.2023.12.030","volume":"80","author":"M Nakano","year":"2024","unstructured":"Nakano M, Kawaguchi M, Kawaguchi T. Almost identical values of various non-invasive indexes for hepatic fibrosis and steatosis between NAFLD and MASLD in Asia. J Hepatol. 2024;80:e155\u20137.","journal-title":"J Hepatol"},{"key":"4806_CR16","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/hep.26594","volume":"58","author":"T Ishimoto","year":"2013","unstructured":"Ishimoto T, Lanaspa MA, Rivard CJ, Roncal-Jimenez CA, Orlicky DJ, et al. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology. 2013;58:1632\u201343.","journal-title":"Hepatology"},{"key":"4806_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00418-025-02402-4","volume":"163","author":"SM Alwahsh","year":"2025","unstructured":"Alwahsh SM, Xu M, Itmezeh A, Kim MH, Ramadori GP. Excessive intake of fructose and alcohol aggravates high-fat diet-induced steatohepatitis and changes hepatic iron homeostasis. Histochem Cell Biol. 2025;163:77.","journal-title":"Histochem Cell Biol"},{"key":"4806_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","volume":"12","author":"S Ishibashi","year":"2018","unstructured":"Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S, et al. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol. 2018;12:173\u201384.","journal-title":"J Clin Lipidol"},{"key":"4806_CR19","doi-asserted-by":"publisher","first-page":"42477","DOI":"10.1038\/srep42477","volume":"7","author":"Y Honda","year":"2017","unstructured":"Honda Y, Kessoku T, Ogawa Y, Tomeno W, Imajo K, Fujita K, et al. Pemafibrate, a novel selective peroxisome proliferatoractivated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep. 2017;7:42477.","journal-title":"Sci Rep"},{"key":"4806_CR20","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.3390\/ijms23073418","volume":"23","author":"H Yanai","year":"2022","unstructured":"Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular biological and clinical understanding of the statin residual cardiovascular disease risk and peroxisome proliferator-activated receptor alpha agonists and ezetimibe for its treatment. Int J Mol Sci. 2022;23:3418.","journal-title":"Int J Mol Sci"},{"key":"4806_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology"},{"key":"4806_CR22","doi-asserted-by":"publisher","first-page":"842","DOI":"10.3390\/diagnostics10100842","volume":"10","author":"Y Seko","year":"2020","unstructured":"Seko Y, Yano K, Takahashi A, Okishio S, Kataoka S, Okuda K, et al. The appropriate opportunity for evaluating liver fibrosis by using the FIB-4 index in patients with nonalcoholic fatty liver disease in Japan. Diagnostics (Basel). 2020;10:842.","journal-title":"Diagnostics (Basel)"},{"key":"4806_CR23","first-page":"120","volume":"40","author":"H Kodama","year":"2018","unstructured":"Kodama H, Itakura H, Ohmori H, Sasaki M, Sando K, Takamura T, et al. Practice guideline for zinc deficiency. J Jpn Soc Clin Nutr. 2018;40:120\u201367. (In Japanese with English abstract).","journal-title":"J Jpn Soc Clin Nutr"},{"key":"4806_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/hepr.13465","volume":"50","author":"I Ozeki","year":"2020","unstructured":"Ozeki I, Arakawa T, Suii H, Tatsumi R, Yamaguchi M, Nakajima T, et al. Zinc deficiency in patients with chronic liver disease in Japan. Hepatol Res. 2020;50:396\u2013401.","journal-title":"Hepatol Res"},{"key":"4806_CR25","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.3945\/jn.115.216093","volume":"145","author":"W Zhong","year":"2015","unstructured":"Zhong W, Li Q, Sun Q, Zhang W, Zhang J, Sun X, et al. Preventing gut leakiness and endotoxemia contributes to the protective effect of zinc on alcohol-induced steatohepatitis in rats. J Nutr. 2015;145:2690\u20138.","journal-title":"J Nutr"},{"key":"4806_CR26","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1007\/BF01535784","volume":"33","author":"S Karayalcin","year":"1988","unstructured":"Karayalcin S, Arcasoy A, Uzunalimoglu O. Zinc plasma levels after oral zinc tolerance test in nonalcoholic cirrhosis. Dig Dis Sci. 1988;33:1096\u2013102.","journal-title":"Dig Dis Sci"},{"key":"4806_CR27","first-page":"143","volume":"30","author":"J Sch\u00f6lmerich","year":"1983","unstructured":"Sch\u00f6lmerich J, Becher MS, K\u00f6ttgen E, Rauch N, H\u00e4ussinger D, L\u00f6hle E, et al. The influence of portosystemic shunting on zinc and vitamin A metabolism in liver cirrhosis. Hepatogastroenterology. 1983;30:143\u20137.","journal-title":"Hepatogastroenterology"},{"key":"4806_CR28","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1002\/hep.510290531","volume":"29","author":"HI Davidson","year":"1999","unstructured":"Davidson HI, Richardson R, Sutherland D, Garden OJ. Macronutrient preference, dietary intake, and substrate oxidation among stable cirrhotic patients. Hepatology. 1999;29:1380\u20136.","journal-title":"Hepatology"},{"key":"4806_CR29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.14740\/jocmr3374w","volume":"10","author":"K Katayama","year":"2018","unstructured":"Katayama K, Kawaguchi T, Shiraishi K, Ito T, Suzuki K, Koreeda C, et al. The prevalence and implication of zinc deficiency in patients with chronic liver disease. J Clin Med Res. 2018;10:437\u201344.","journal-title":"J Clin Med Res"},{"key":"4806_CR30","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/jcm8030336","volume":"8","author":"H Nishikawa","year":"2019","unstructured":"Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, et al. Serum zinc concentration and sarcopenia: a close linkage in chronic liver diseases. J Clin Med. 2019;8:336.","journal-title":"J Clin Med"},{"key":"4806_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5114\/ceh.2024.143072","volume":"10","author":"M Kikuchi","year":"2024","unstructured":"Kikuchi M, Kikuchi M, Konishi M. Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia. Clin Exp Hepatol. 2024;10:182\u20137.","journal-title":"Clin Exp Hepatol"},{"key":"4806_CR32","doi-asserted-by":"publisher","first-page":"172","DOI":"10.5114\/ceh.2021.106864","volume":"7","author":"S Shinozaki","year":"2021","unstructured":"Shinozaki S, Tahara T, Lefor AK, Ogura M. Pemafibrate improves hepatic inflammation, function and fibrosis in patients with non-alcoholic fatty liver disease: a one-year observational study. Clin Exp Hepatol. 2021;7:172\u20137.","journal-title":"Clin Exp Hepatol"},{"key":"4806_CR33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.5114\/ceh.2020.99528","volume":"6","author":"S Shinozaki","year":"2020","unstructured":"Shinozaki S, Tahara T, Lefor AK, Ogura M. Pemafibrate decreases markers of hepatic\u3000inflammation in patients with non-alcoholic fatty liver disease. Clin Exp Hepatol. 2020;6:270\u20134.","journal-title":"Clin Exp Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04806-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04806-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04806-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:15:21Z","timestamp":1778721321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04806-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4806"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04806-5","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethics committee of Toho University (number M23242 21002) and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all the study participants before enrollment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"293"}}